Acadra (acadesine)
/ Advancell
- LARVOL DELTA
Home
Next
Prev
1 to 8
Of
8
Go to page
1
December 29, 2020
Acadesine suppresses TNF-α induced complement component 3 (C3), in retinal pigment epithelial (RPE) cells.
(PubMed, PLoS One)
- "Our results suggest that acadesine suppresses TNF-α induced C3, likely through an AMPK-independent pathway, and could have potential use in complement over activation diseases."
Journal • Age-related Macular Degeneration • Complement-mediated Rare Disorders • Immunology • Inflammation • Macular Degeneration • Ophthalmology • Retinal Disorders • TNFA
February 07, 2019
A prospective targeted serum metabolomics study of pancreatic cancer in postmenopausal women.
(PubMed, Cancer Prev Res (Phila))
- "The area under the ROC curve was 0.83 in the discrimination analysis based on the levels of L-1MT, acadesine, and aspartic acid. None of the metabolites was validated in additional independent 18 case/control pairs. No significant association was found between the examined metabolites and undiagnosed pancreatic cancer."
Clinical • Journal • Gastrointestinal Cancer • Oncology • Pancreatic Cancer • Solid Tumor • Women's Health
December 30, 2019
Acadesine Circumvents Azacitidine Resistance in Myelodysplastic Syndrome and Acute Myeloid Leukemia.
(PubMed, Int J Mol Sci)
- "Despite a very good response in one out 4 patients, we stopped this trial because the highest Aca dose (210 mg/kg) caused serious renal side effects in several patients. In conclusion, the side effects of high Aca doses preclude its use in patients with strong comorbidities."
Journal • Acute Myelogenous Leukemia • Hematological Disorders • Hematological Malignancies • Leukemia • Myelodysplastic Syndrome • Oncology
April 23, 2016
AICAR induces AMPK-independent programmed necrosis in prostate cancer cells.
(PubMed)
-
Biochem Biophys Res Commun
- "AICAR (5-Aminoimidazole-4-carboxamide riboside or acadesine) is an AMP-activated protein kinase (AMPK) agonist, which induces cytotoxic effect to several cancer cells...CYPD inhibitors (cyclosporin A and sanglifehrin A) as well as CYPD shRNAs dramatically attenuated AICAR-induced prostate cancer cell necrosis and cytotoxicity...ROS scavengers (N-acetylcysteine and MnTBAP), but not AMPKα shRNAs, largely inhibited prostate cancer cell necrosis and cytotoxicity by AICAR. In summary, the results of the present study demonstrate mechanistic evidences that AMPK-independent programmed necrosis contributes to AICAR's cytotoxicity in prostate cancer cells."
Journal • Biosimilar • Genito-urinary Cancer • Oncology • Prostate Cancer
November 17, 2016
AICAR activates ER stress-dependent apoptosis in gallbladder cancer cells.
(PubMed)
-
Biochem Biophys Res Commun
- "AICAR (5-Aminoimidazole-4-carboxamide riboside or acadesine) is an AMP-activated protein kinase (AMPK) agonist, its activity in human gallbladder cancer cells was evaluated here. Contrarily, salubrinal (the ER stress inhibitor), z-ATAD-fmk (the caspase-12 inhibitor) or CHOP shRNAs significantly attenuated AICAR-induced gallbladder cancer cell apoptosis. Together, we conclude that AICAR-induced gallbladder cancer cell apoptosis requires ER stress activation, but is independent of AMPK."
Journal • Biosimilar • Bladder Cancer • Gastrointestinal Cancer • Oncology • Urothelial Cancer
June 15, 2018
Synthesis of C-labeled 5-Aminoimidazole-4-carboxamide-1-β-D-[ C ] ribofuranosyl 5'-monophosphate.
(PubMed, J Labelled Comp Radiopharm)
- "Our method employs a hybrid enzymatic and chemical synthesis approach that applies an enzymatic conversion from adenosine to inosine followed by a ring-cleavage of the protected inosine. A direct phosphorylation of the resulting 2',3'-isopropylidine acadesine (5) was developed to yield the title compound in 99% purity following ion exchange chromatography."
Journal
January 19, 2018
The role of AMPK/mTOR modulators in therapy of acute myeloid leukemia.
(PubMed, Curr Med Chem)
- "...Numerous studies demonstrate that drugs that inhibit mechanistic target of rapamycin (mTOR) and activate AMP-kinase (AMPK) have beneficial effects in promoting differentiation and blocking proliferation of AML. Most of these drugs are already in use for other purposes; rapalogs as immunosuppressants, biguanides as oral antidiabetics, and 5-amino-4-imidazolecarboxamide ribonucleoside (AICAr, acadesine) as an exercise mimetic. Although most of these pharmacological modulators have been widely used for decades, their mechanism of action is only partially understood. In this review, we summarize the role of AMPK and mTOR in hematological malignancies and discuss the possible role of pharmacological modulators in proliferation and differentiation of leukemia cells."
Journal
October 07, 2018
The Chinese medicine Chai Hu Li Zhong Tang protects against non-alcoholic fatty liver disease by activating AMPKα.
(PubMed, Biosci Rep)
- "The AMPK agonist, acadesine (AICAR), was used as a positive control compound. CHLZT protects against NAFLD by activating AMPKα, and also by inhibiting ACC activity, downregulating SREBP2 and HMGR, and upregulating PPAR-γ. Our results suggest that CHLZT might be useful for treating NAFLD in the clinic."
Journal
1 to 8
Of
8
Go to page
1